LION bioscience Launches piScout(TM) Software for Molecular Network Analysis
HEIDELBERG, Germany, June 18 /PRNewswire/ -- LION bioscience AG (Nasdaq: LEON; Neuer Markt: LIO, WKN 504 350) today announced the release of piSCOUT(TM) 1.0, a unique software package for the interactive visualization of relationships between molecules such as protein interactions. The application supports comfortable navigation through large amounts of scientific findings in order to understand complex cellular processes more rapidly. piSCOUT(TM) and pathSCOUT(TM), which was also released today, are new modules for LION's integrated Life Science Informatics Platform which is being developed to shorten product development cycles in the Life Science industry.
"piSCOUT(TM) emerged from our internal need to intuitively visualize protein interaction data generated in LION's drug discovery department," said Dr. Jan Michel, Product Manager for Life Science Informatics. "Having considerably broadened the initial concept, we are now providing our customers with the ability to view and analyze their own findings together with information from the public domain, and to use that combined information, among other things, to facilitate the interpretation of gene expression data from microarray experiments."
Mapping all the interactions of an organism's proteome is an important step towards the functional characterization of individual proteins. Furthermore, a wealth of disconnected findings exist in scientific literature, describing relationships between genes or proteins as well as between proteins and small molecules. piSCOUT(TM) provides the ability to import and connect these findings, and to graphically explore the resulting networks of inter- molecular relationships. The tight integration with LION's enterprise system for expression data analysis, arraySCOUT(TM), enables users to directly investigate the regulation of genes that are part of any network of inter- molecular relationships.
piSCOUT(TM) allows the seamless import of existing public protein interaction databases and supports the Biomolecular Interaction Network Database (BIND) XML standard file format (http://binddb.org).
For more information on piSCOUT(TM) please visit lionbioscience.com
About LION bioscience AG:
LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genetics to early and late discovery through clinical trials. LION offers these solutions via two primary lines of business:
-- i-biology(R): the installation and implementation of enterprise-wide
horizontal information and knowledge management solutions as part of
LION's Life Science Informatics (LSI(TM)) line of business; and
-- Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
i-biology(R) to LION's internal drug discovery program with the goal
to out-license specific databases, polymorphism marker panels, and
validated targets and leads.
Founded in 1997, LION, together with its consolidated subsidiaries, has more than 440 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, GMD, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Sumitomo Pharmaceuticals and Tripos.
All statements in this press release that are not historical are forward-looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. These and other risk factors are discussed in LION's Registration Statement on Form F-4 declared effective by the SEC on February 9, 2001. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein.
LION bioscience(R) and i-biology(R) are either registered trademarks of LION bioscience AG in the United States and/or other countries, or LION bioscience AG has pending applications for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners. Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in the United States. Trega(R) is a registered trademark of Trega Biosciences, Inc.
CONTACT: Dr. Andrea Kreisselmeier
Director, Corporate Marketing & Communications
LION bioscience AG
49-0-6221-4038-265
andrea.kreisselmeier@lionbioscience.com
Matthew Scampoli
Noonan-Russo Communications
212-696-4455, ext. 243
m.scampoli@noonanrusso.com,
for LION bioscience AG
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE LION bioscience AG
CO: LION bioscience AG
ST: Germany
IN: MTC BIO STW
SU: PDT
06/18/2001 01:30 EDT prnewswire.com |
